Potent antitumor activity of the acyclic nucleoside phosphonate 9-(2- phosphonylmethoxyethyl)adenine in choriocarcinoma-bearing rats

International Journal of Cancer

Volumn 76, Issue 4, 1998, Pages 595-600

  Hatse, S ^a   Naesens, L ^a   Degreve B ^a,c   Segers, C ^b   Vandeputte, M ^a   Waer, M ^b   De Clercq, E ^a   Balzarini, J ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Rega Institute for Medical Research ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACYCLIC NUCLEOSIDE; ADEFOVIR; ADEFOVIR DIPIVOXIL; ANTIRETROVIRUS AGENT; METHOTREXATE; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CHORIOCARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY CAPSULE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR REGRESSION; TUMOR VOLUME;

ADENINE; ANIMALS; ANTIVIRAL AGENTS; CHORIOCARCINOMA; DRUG ADMINISTRATION SCHEDULE; NEOPLASM TRANSPLANTATION; PHOSPHONIC ACIDS; PRODRUGS; RATS; RATS, INBRED STRAINS; TUMOR CELLS, CULTURED;

EID: 0031959968     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980518)76:4<595::AID-IJC24>3.0.CO;2-5     Document Type: Article

References (20)

1. BALZARINI, J., NAESENS, L. and DE CLERCQ, E., Anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in vivo increases when it is less frequently administered. Int. J. Cancer. 46, 337-340 (1990).
2. BALZARINI, J., VERSTUYF, A., HATSE, S., GOEBELS, J., SOBIS, H., VANDEPUTTE, M. and DE CLERCQ, E., The human immunodeficiency virus (HIV) inhibitor 9-(2-phosphonylmethoxyethyl)adenine (PMEA) is a strong inducer of differentiation of several tumor cell lines. Int. J. Cancer, 61, 130-1371 (1995).
3. BARDITCH-CROVO, P., TOOLE, J., HENDRIX, C.W., CUNDY, K.C., EBELING, D., JAFFE, H.S. And LIETMAN, P.S., Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefvoir dipivoxil (9-[2-(bispivaloyloxymethl)-phosphonylmethoxyethyl] in HIV-infected patients. J. Infect. Dis., 176, 406-413 (1997).
4. BOTTE, V., TRAMONTANA, S. and CHIEFFI, G., Histochemical distribution of some hydroxysteroid dehydrogenase in the placenta, foetal membrance and uterine mucosa of the mouse. J. Endocrinol., 40, 189-194 (1968).
5. CALIO, R., VILLANI, N., BALESTRA, E., SESA, F., HOLÝ, A., BALZARINI, J., DE CLERCQ, E., PERNO, C.F. and DEL GOBBO, V., Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Res., 23, 77-89 (1994).
6. CUNDY, K.C., BARDITCH-CROVO, P., WALKER, R.E., COLLIER, A.C., EBELING, D., TOOLE, J. and JAFFE, H.S., Clinical pharmacokinetics of adefovir in human immunodeficiency virus type-1 infected patients. Antimicrob. Agents Chemother., 39, 2401-2405 (1995).
7. DE CLERCQ, E., HOLÝ, A., ROSENBERG, I., SAKUMA, T., BALZARINI, J. and MAUDGAL, P.C., A novel selective broad-spectrum anti-DNA virus agent. Nature (Lond.), 323, 464-467 (1986).
8. DEL GOBBO, V., FOLI, A., BALZARINI, J., DE CLERCQ, E., BALESTRA, E., VILLANI, N., MARINI, S., PERNO, C.F. and CALIO, R., Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models. Antiviral Res., 16, 65-75 (1991).
9. HATSE, S., DE CLERCQ, E. and BALZARINI, J., Evidence for distinction of the differentiation-inducing activities and cytostatic properties of 9-(2-phosphonylmethoxyethyl)adenine and a variety of differentiation-inducing agents in human erythroleukemia K562 cells. Mol. Pharmacol., 50, 1231-1242 (1996).
10. HATSE, S., NAESENS, L., DE CLERCQ, E. and BALZARINI, J., Potent differentiation-inducing properties of the anti-retroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in the rat choriocarcinoma RCHO tumor cell model. Biochem. Pharmacol. (1998). (In press).
11. HOLÝ, A. and ROSENBERG, I., Synthesis of 9-(2-phosphonylmethoxyethyl) adenine and related compounds. Collect. Czech. chem. Comm., 52, 2801-2809 (1987).
12. NAESENS, L., BALZARINI, J. and DE CLERCQ, E., Therapeutic potential of PMEA as an antiviral drug. Rev. med. Virol., 4, 147-159 (1994).
13. NAESENS, L., BALZARINI, J., ROSENBERG, I., HOLÝ A. and DE CLERCQ, E., 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP): a novel agent with anti-human immunodeficiency virus activity in vitro and potent anti-Moloney murine sarcoma virus activity in vivo. Europ. J. clin. Microbiol. infect. Dis., 8, 1043-1047 (1989).
14. OTOVá, B., KŘENOVǍ, K., ZǏDEK, Z., HOLÝ, A., VOTRUBA, I. and KŘEN, V., Cytostatic effect of 9-(2-phosphonylmelhoxyethyl)adenine (PMEA). III. Rat and mouse carcinomas and sarcomas. Folia Biol. (Praha). 39,311-314 (1993).
15. POMMIER, Y. and LOKIEC, F., Le méthotrexate. Chimiothér. Anticancer., 31, 3083-3089 (1981).
16. SOBIS, H. and VANDEPUTTE, M., Development of teratomas from displaced visceral yolk sac. Int. J. Cancer, 13, 444-453 (1974).
17. TESHIMA, S., SHIMOSATO, Y., KOIDE, T., KUROKI, M., KIKUCHI, Y. and AIZAWA, M., Transplantable choriocarcinoma of rats induced by fetectomy and its biological activities. Jap. J. Cancer Res., 74, 205-212 (1983).
18. TSAI, C.-C., FOLLIS, K.E., SABO, A., BECK, T.W., GRANT, R.F., BISCHOF-BERGER, N., BENVENISTE, R.E. and BLACK, R., Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science, 270, 1197-1199 (1995).
19. VERSTUYF, A., SOBIS, H., GOEBELS, J., FONTEYN, E., CASSIMAN, J.J. and VANDEPUTTE, M., Establishment and characterization of a continuous in vitro line from a rat choriocarcinoma. Int. J. Cancer, 45, 752-756 (1990).
20. VERSTUYF, A., SOBIS, H. and VANDEPUTTE, M., Morphological and immunological characteristics of a rat choriocarcinoma. Int. J. Cancer, 44, 879-884 (1989).